Diego da Rosa Miltersteiner

Uso de quercetina a longo prazo em ratos cirróticos

PURPOSE: The long term use of quercetin flavonoid was evaluated in cirrhotic rats by common biliary duct bondage (LDB). METHODS: 32 male Wistar rats were submitted to LDB or simulation, and distributed in 4 groups: 1) control, 2) cirrhotic, 3) cirrhotic treated with quercetin the second day after the surgical procedure; and 4) cirrhotic treated with quercetin after the fourteenth day of the surgical procedure. The hepatic function was analyzed through biochemical tests (TB and DB) and enzymatic activity (ALT, AST, AP and GGT). In the anatomopatological analysis, Hematoxilin & Eosin (HE Group 2 = 46 days; Group 3 = 71 days; and the Group 4 = 90 days. In the animals with bondage of common biliary duct, there was an increase of the hepatic and anzymatic function tests, which was reduced with the treatment with quercetin. Cirrhosis, portal and centrolobular vascular congestion, were identified in the histopatological analysis with H&E and Picrosirius. CONCLUSION: The use of quercetin decreased significantly the biochemical alterations caused by cirrhosis, increasing the time of survival of the animals with secondary biliary cirrhosis due to LDB.

Risk of hypoglycemia during hemodialysis in diabetic patients is related to lower pre-dialysis glycemia

OBJECTIVE To compare the occurrence of hypoglycemia during hemodialysis in chronic kidney disease diabetic patients who present different levels of pre-dialysis glycemia both when using dialysis solutions with and without glucose. SUBJECTS AND METHODS Twenty type 2 diabetic patients in maintenance hemodialysis were submitted to three dialysis sessions (at a 7-day interval each) with dialysis solutions without glucose, with glucose at 55 mg/dL, and at 90 mg/dL subsequently. Blood glucose levels were measured immediately pre-dialysis and at 4 moments during the session, and values under 70 mg/dL were considered as hypoglycemia. RESULTS Average pre-dialysis glycemia was lower in those who presented intra-dialytic hypoglycemia than in those who did not, both in glucose-free (140.4 ± 50.7 vs. 277.7 ± 91.0 mg/dL; p = 0.005; 95%CI: 46.4 to 228.1) and in glucose 55 mg/dL (89.5 ± 10.6 vs. 229.7 ± 105.0 mg/dL; p < 0.05; 95%CI: 9.8 to 270.5). In patients with pre-dialysis glycemia under 140 mg/dL, average intradialytic glycemia was significantly lower than pre-dialysis glycemia only when using glucose-free dialysate (p < 0.0001; 95%CI: 29.9 to 56.0 - t-test). Hypoglycemia during dialysis was observed only when using glucose-free or glucose-poor dialysis solutions. CONCLUSIONS The use of glucose-free or glucose-poor dialysis solution presents a high risk of intradialytic hypoglycemia in diabetic renal patients, especially in those with presumed better glycemic control.